SCHEMBL15512802

SCHEMBL15512802

CC(O)n1cc(N)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3795135 0.98 ACHE (0.33)
SCHEMBL23210447 0.83 JAK2 (0.36)
SCHEMBL574538 0.82
Hydrochloric Acid SCHEMBL15875416 0.80 ACHE (0.43)
SCHEMBL15651247 0.79 JAK2 (0.38)
SCHEMBL17076736 0.78 ACHE (0.31)
SCHEMBL26775818 0.78
SCHEMBL15894923 0.78 JAK2 (0.39)
SCHEMBL15894956 0.78 JAK2 (0.39)
SCHEMBL1662833 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3990449-A1 HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) 2022-05-04 EP disclosed
WO-2020259584-A1 HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) 2020-12-30 WO disclosed
CN-104736533-B Vegfr3 inhibitor 癌症治疗合作研究中心有限公司 2016-12-07 CN disclosed
US-9238644-B2 VEGFR3 inhibitors CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2016-01-19 US disclosed
US-20160009686-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2016-01-14 US disclosed
CN-104736533-A VEGFR3 inhibitors CANCER THERAPEUTICS CRC PTY LTD 2015-06-24 CN disclosed
US-20140073620-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-03-13 US disclosed